Navigation Links
Schizophrenic in Medical News

Improving the prognosis for schizophrenic disorders

Throughout the world, scientists are attempting to recognize and treat schizophrenic disorders at an earlier stage. It is hoped that this will improve the prognosis, which has often been unfavorable. In the latest edition of Deutsches rzteblatt International ( Dtsch Arztebl Int 2008; 105[30]: 5...

Cognitive rehabilitation holds promise for schizophrenic brain function improvements

Study had shown that it is possible to improve the brain functions of schizophrenic// patients through cognitive rehabilitation programs. Researchers from Washington University in St. Louis have suggested that memorization strategies used by normal people to remember things may be useful for s...

Music to help schizophrenic patients

Scientists have found that in addition to schizophrenic patients being given medical care, music, as a therapy, can bring about changes in their general sense of well being, mental state and social activities.// Since 1950s music had been used as a therapy for people with serious mental disord...

Alexza to Announce 2009 Second Quarter Financial Results and Update Its Clinical Pipeline Status on Wednesday, August 5, 2009

...comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Columbia leads national effort to develop early intervention for schizophrenia

...ders by dramatically slowing progression; reducing disability, mortality, and the expense of care; and increasing recovery. The Recovery After Initial schizophrenic Episode (RAISE) study, funded at $9.9 million for two years, has the potential to be extended to six years and a total of $21.3 million if certain mil...

Study finds cancer is the second most frequent cause of death in individuals with schizophrenia

...tify characteristics that might help predict which schizophrenic patients are likely to develop cancer. The rese...he general population (56.3 vs. 33.0%). In female schizophrenic patients, the risk of death due to breast cancer w...ing less attention to symptoms; the difficulty for schizophrenic patients to benefit from optimum treatment; and le...

Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Alexza's Corporate Presentation to be Webcast at the Piper Jaffray Fourth Annual Europe Conference

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications

...including SEROQUEL. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatmen...

Alexza's Corporate Presentation to be Webcast at the Eighth Annual JMP Securities Research Conference

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications

...cluding quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatmen...

FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications

...cluding quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatmen...

FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site

...cluding quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatmen...

Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status

...lts from its first Phase 3 clinical trial of AZ-004 in 344 acutely agitated schizophrenic patients. The study design was similar to the clinical trial outlined abov...o loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive ...

Alexza's Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009

...ent comfort and convenience. Alexza's lead program is AZ-004 (Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression

...cluding quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatmen...

Common Genes Link Bipolar Disorder, Schizophrenia

...to the study, published in this week's edition of The Lancet , brothers or sisters of people with these conditions were nine times more likely to be schizophrenic and had eight times the risk of developing bipolar disorder. The odds were less steep but still high for half-siblings. Brothers and sisters with...

Eli Lilly Pays a Record $1.4 Billion to Settle Federal and State Fraud Investigations into Illegal Zyprexa Off-Label Marketing Practices

...ties because Zyprexa is not approved for any use in that patient population in addition to the fact that the typical residents of these homes were not schizophrenic or bipolar. "Our clients questioned their superiors about the legality of Lilly's Zyprexa marketing practices," explained Deming, "but they were inst...

Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa

...n place of the management of the manifestations of psychotic disorders. Also in Nov. 2000, FDA approved Zyprexa for maintaining treatment response in schizophrenic patients who had been stable for approximately eight weeks and were then followed for a period of up to eight months. Zyprexa has never been approved...

Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts

... Alexza has five product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, has completed one Phase 3 clinical trial and enrolled a second Phase 3 trial. The Company has completed its end-of-Phase...

Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates

...from its first Phase 3 clinical trial of AZ-004 in schizophrenic patients with acute agitation. Both the 5 mg and t...rability and pharmacokinetic study in non-agitated schizophrenic patients, and a 344 patient Phase 3 study in schizophrenic patients with acute agitation. Alexza completed an...

Alexza to Announce 2008 Third Quarter Financial Results and Update Its Clinical Pipeline on Thursday, November 6, 2008

... Alexza has five product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, has completed one Phase 3 clinical trial and enrolled a second Phase 3 trial. The Company has completed its end-of-Phase...

Summary Judgment Granted for SEROQUEL(R) Patent Litigation

... including SEROQUEL. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatment...

Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations

... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Ph...

Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.

...hich is in Phase 3 clinical testing for the treatment of acute agitation in schizophrenic or bipolar disorder patients. Mr. Williams will continue to serve as the ...program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato proch...

Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality

... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Ph...

Alexza's Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference

... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Ph...

FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder

...ncluding quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatment...

Alexza to Webcast Investor and Analyst Day Presentations

...), and discuss the role that AZ-004 may play in treating acute agitation in schizophrenic or bipolar disorder patients. Alexza senior management will also provide an...program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato proch...

First do no harm? UH prof taking opposite approach to treat asthma

...nd the skin irritant retinoic acid is used to treat acne. Additionally, there has been research into using antipsychotic drugs traditionally used for schizophrenic patients to decrease the incidence of Alzheimers disease by suppressing the dopamine system, which is hypoactive in such neurodegenerative diseases. ...

Restrictive Prescription Drug Policies Hurt Schizophrenics

... study authors said. "Given the tremendous variation in individual responses to drugs as well as the devastating impact of treatment disruptions on schizophrenic patients, a policy that pushes all patients toward a limited number of preferred drugs may do more harm than good," Soumerai said. "It would be much b...

Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.

... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Ph...

Alexza's Corporate Presentation to be Webcast at the Cowen & Company 28th Annual Health Care Conference

... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Ph...

Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008

...s of its Phase IIa clinical trial of AZ-004 in 129 schizophrenic patients with acute agitation. In that trial, the ...nistering the injection. Alexza believes that many schizophrenic and bipolar patients can make informed decisions r...cting, noninvasive treatment of acute agitation in schizophrenic and bipolar patients. Conference Call At 5:00 p....

FDA Approves First Anti-Psychotic for Kids

...erdal and other drugs that are approved for treating these conditions in adults," Laughren said. The FDA based its approval for using the drug with schizophrenic adolescents on the results of two short-term trials. Patients taking the drug had fewer symptoms, including fewer hallucinations and less delusional t...

NIH Awards Emory $3.6 Million for Schizophrenia Gene Research

... Emory University School of Medicine a $3.6 million research grant to test schizophrenic patients for a recently discovered variation in the human genome. The proje...w major research centers, the Emory project will screen a collection of 500 schizophrenic patients and 500 controls (individuals without schizophrenia) for CNV throu...

Brain Cells Activity: New Treatment Target for Psychiatric Diseases

...tered signaling pathway for neuregulin-1 and ErbB4 genes in the brains of schizophrenics. Dr. Mei's findings show that these factors associated with a schizophrenic brain have at least two places to act. "There is a ton of evidence that when inhibitory synapses, such as GABA, go wrong, the symptoms of mice...

Marijuana can Trigger Psychotic Symptoms, New Study Finds

...healthy subjects experienced psychotic symptoms when given the drug. While the doctors expected to see marijuana improve the conditions of their schizophrenic subjects—since their patients reported that the drug calmed them—they found that the reverse was true. "I was surprised by the results," said Dr...
Other Tags
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
(Date:7/10/2014)... July 1, 2014 Smart technology emphasis ... convenience and improved security: NXT-ID, Inc. (OTCBB: NXTD), eBay Inc. ... GOOG ), Apple Inc. (NASDAQ: AAPL ), Visa ... MA) NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company ... that the second series of 30 second spots on CNBC ...
(Date:7/10/2014)... 2, 2014 It is a great honor ... appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark ... Dr. Ginsburg, with over 34 years of experience, ... and Good Samaritan Regional Medical Center. Dr. Ginsburg has ... 1980,s and is considered an expert in the implantation ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
(Date:7/13/2014)... 13, 2014 Recently, MillionaireCasket.com, a well-known casket ... oak caskets . Additionally, the company’s chief executive officer has ... new oak caskets are offered at discounted prices, from 15 ... concerned, quality caskets are in huge demand in the current ... caskets . We have a lot of high quality products ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 The North American ... million in 2013 to $5,450 million by 2018, at a ... systems market is expanding at a rapid pace in North ... ever tightening laws on water & wastewater storage and collection, ... infrastructure. The market is expanding at a healthy rate in ...
(Date:7/13/2014)... 2014 The report “Micronutrient Market ... Form (Chelated & Non Chelated), Application Mode (Soil, ... Trends and Forecast to 2018” defines and segments ... and forecasting of the global value and volume ... and restraining factors for the global agriculture micronutrients ...
(Date:7/13/2014)... Fuel additives are chemicals, which are added ... kerosene, and so on, in order to enhance their ... corrosion effects caused by fuels and improving the combustion ... provide economies of scale in the long run, but, ... of the fuel products. , The various fuel additive ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on ... 3D rendering; Layout and Animation; Image Reconstruction]: Global ... which analyzes and studies the major market drivers, ... Eastern Europe, Middle East and Africa, Asia-Pacific and ... landscape of the 3D imaging market, providing an ...
Breaking Medicine News(10 mins):Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4
Other Contents